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The concept of cellular plasticity is particularly apt in early embryonic development,
where there is a tug-of-war between the stability and flexibility of cell identity. This
balance is controlled in part through epigenetic mechanisms. Epigenetic plasticity
dictates how malleable cells are to change by adjusting the potential to initiate new
transcriptional programmes. The higher the plasticity of a cell, the more readily it can
adapt and change its identity in response to external stimuli such as differentiation cues.
Epigenetic plasticity is regulated in part through the action of epigenetic priming factors
which establish this permissive epigenetic landscape at genomic regulatory elements to
enable future transcriptional changes. Recent studies on the DNA binding proteins
Developmental Pluripotency Associated 2 and 4 (Dppa2/4) support their roles as epigen-
etic priming factors in facilitating cell fate transitions. Here, using Dppa2/4 as a case
study, the concept of epigenetic plasticity and molecular mechanism of epigenetic
priming factors will be explored. Understanding how epigenetic priming factors function
is key not only to improve our understanding of the tight control of development, but also
to give insights into how this goes awry in diseases of cell identity, such as cancer.
Introduction
Mammalian development starts with a single totipotent zygote, capable of giving rise to all embryonic
and extraembryonic cell types. The potency of early embryonic cells decreases as the embryo develops
and cell fates are specified. The first cell fate decision occurs by the blastocyst stage when embryonic
versus extraembryonic cell fates have been made. Shortly after, the three germ layers are specified
during gastrulation. This plasticity in development, or the ability of cells to adapt to external cues and
adopt new functions or identities, is regulated in part by the epigenome. While all cells at all stages of
embryonic development contain the same genetic information, the availability of this DNA content is
tightly regulated through epigenetic mechanisms which direct gene expression programmes to provide
cell identity while simultaneously priming cells for change.
The epigenome undergoes dramatic changes during the early stages of development (reviewed in
[1–4]) (Figure 1). In mammals, DNA methylation is found predominantly on cytosine bases when fol-
lowed by a guanine (CpG), and is generally associated with gene repression (reviewed in [5,6]). The
majority of somatic cells, including the mature gametes, have high levels of CpG methylation.
However, following fertilisation there is a global loss of DNA methylation which is only reinstated at
the onset of gastrulation following implantation (Figure 1). Similarly, the chromatin landscape also
changes dramatically during early development. Globally, the higher-order chromatin structure in
zygotes is relaxed and loose, and becomes progressively more structured and ordered as development
progresses [7,8]. At the level of the nucleosomes, the histones that make up chromatin are extensively
post-translationally modified, and the pattern of acetyl, methyl, and other modifications reflects the
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accessibility and activity of the underlying genetic information. These histone modification patterns, while rela-
tively stable in differentiated cells, undergo dynamic changes during early embryonic development (reviewed in
[1,9]). It is thought that these global DNA methylation and chromatin dynamics resets the epigenetic landscape
in early embryos, increasing cellular plasticity and facilitating the developmental potential of the cells.
By regulating gene expression, epigenetics has the potential not only to define current cell states but to shape
how cells respond to external cues such as differentiation or stress. Epigenetic plasticity describes how malleable
or flexible this regulation is: highly plastic cells have a wide range of cell identities available to them while non-
plastic cells are static and unresponsive. By maintaining the chromatin in a state that has the potential to
become either activated or repressed, epigenetic plasticity gives cells the flexibility to adopt different cell fates or
functions. Similar to cell potency, epigenetic plasticity is a continuum of states and generally decreases as devel-
opment progresses. How this epigenetic plasticity is regulated and its impact on embryonic development
is only beginning to be understood. Here, the role epigenetic priming factors play in facilitating epigenetic
plasticity will be explored, using the DNA binding proteins Developmental Pluripotency Associated 2 and 4
(Dppa2/4) as exemplars of this emerging class of epigenetic regulators.
What is an epigenetic priming factor and how could
they work?
Epigenetic priming factors generate a permissive epigenetic landscape that facilitates future activation of gene
expression programmes. This primed epigenetic landscape can take place at a range of genomic elements,
including promoters and enhancers, and comes in many forms. Perhaps the best understood is the case of
bivalent chromatin at promoters (reviewed in [10,11]). In pluripotent cells, this co-occurrence of both active
Figure 1. Epigenetic dynamics during early mammalian embryonic development.
Zygotic genome activation (ZGA) occurs in two waves (orange line) in the late zygote and two cell stage (four to eight cell stage
in humans) as maternal mRNA (aqua line) is degraded. Concurrently, there is a global wave of DNA demethylation and
remethylation (blue line), an acquisition of chromatin bivalency (magenta line) as the higher order chromatin structure becomes
more ordered (green). During gastrulation cell identities become more refined as the epigenome becomes more structured.
Note embryo schematics are not to scale and timings are approximate and based on murine development.
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associated H3K4me3 and repressive associated H3K27me3 modifications keeps developmental genes primed
for future activation or silencing upon differentiation [12,13]. Promoters can also be primed by histone acetyl-
ation which is observed at ZGA-related promoters in Zebrafish where H3K27 acetylation marks promoters
prior to their activation [14], and Drosophila where maternal H4K16 acetylation primes ZGA genes for future
gene activation [15]. In addition to histone modifications, histone variants can also prime genes, which is
observed in the case of the H2A variant H2A.Z(FV) which acts as a ‘placeholder’ at ZGA promoters in zebra-
fish embryos prior to their activation [16]. Priming also extends beyond promoters. Enhancers are frequently
found inactive yet marked by H3K4me1 (primed enhancers) or the combination of H3K4me1, p300 and
H3K27me3 (poised enhancers) [17,18]. These enhancer classes only acquire the ability to activate their target
genes at later developmental stages (reviewed in [19]). In addition to chromatin features, poised RNA polymer-
ase II [20] and/or antisense transcription [21] at epigenetically primed loci can help keep the locus permissive
for future activation. This variety of diverse chromatin structures at a range of genomic features, including
potentially many more still undiscovered, likely provide both specificity and redundancy in priming the under-
lying sequence for future activation. The identity and function of the priming factors required for the establish-
ment and/or maintenance of these epigenetic landscapes is an ongoing area of research.
Predicted features of epigenetic priming factors
There are several features of epigenetic priming factors that make them unique from other epigenetic and tran-
scriptional regulators. One key feature of priming factors is the temporal uncoupling between the time they
exert their molecular effects and resulting transcriptional and/or phenotypic consequences. For example, an
epigenetic priming factor may prime gene regulatory elements in cell type A which are not required by that cell
per se but are activated when the cell receives an external signal. Removing the epigenetic priming factor from
cell type A would have minor phenotypic effects, however, this cell would now no longer be able to respond
efficiently to the signal (Figure 2A). This has recently been elegantly shown in C. elegans where transient
expression of TBX-37/38 primes the lsy-6 gene for future activation 4 cell cycles later at a time when TBX37/38
is no longer expressed [21]. Additionally, in mammals priming factors bind and mark the albumin enhancer in
precursor gut endoderm where it is inactive until hepatic specification later in development [22].
Epigenetic priming factors may have pioneer activity although this is not a requirement. Pioneer factors are
able to bind DNA that is tightly packaged around a nucleosome thereby opening up otherwise inaccessible
chromatin structures (reviewed in [23]). For example, the pioneer factor Zelda primes early zygotic enhancers
in Drosophila, facilitating the subsequent binding of other factors during zygotic genome activation [24,25].
Moreover, in zebrafish, the pioneer factor Foxd3 recruits Brg1 to mediate chromatin priming and chromatin
remodelling in early neural crest development [26]. In mouse ESCs, Foxd3 also has roles in priming enhancers,
such as the Alb1 enhancer, marking this enhancer for activation in later lineages [27]. However, while pioneer-
ing activity is obviously an advantage, it may not be a necessity in early development where the global epigen-
etic dynamics could enable factors without pioneering activity to bind their target sites.
Another important consideration is that initiating and maintaining an epigenetically primed structure are
not necessarily performed by the same molecules. While epigenetic priming factors may be required to estab-
lish the primed state, this could be maintained and perpetuated in the absence of the initial trigger by the epi-
genetic machinery. For example, active genes can be maintained through positive feedback mechanisms
between RNA polymerase II and trithorax group proteins [28] in the absence of the initiating transcription
factor. Likewise, DNA methylation can be maintained through mitosis by the maintenance DNA methyltrans-
ferase Dnmt1, even if the de novo DNA methyltransferases Dnmt3a/3b are no longer being targeted to these
sites. In this way, epigenetic priming factors do not need to continuously target their epigenetic state once they
are established.
Epigenetic priming factors may have subtle roles in assisting cell fate transitions, acting as facilitators rather
than gatekeepers of cell identity. By creating a permissive epigenetic environment at their targets, epigenetic
priming factors may increase the frequency or temporal dynamics of target gene activation to ensure timely
and efficient adaptation of transcriptional programmes. While key regulators are necessary for the acquisition
of new transcriptional programmes, epigenetic priming factors function more as facilitators, preparing cells for
change, and may not be absolutely required. As such, manipulating levels of priming factors may result in
subtle or delayed phenotypes, rather than complete absence expected for essential regulators, as is seen in the
case of Dppa2/4 (see below) [29,30]. It is also likely that epigenetic priming factors have additional roles
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Figure 2. Mechanisms and significance of epigenetic priming. Part 1 of 2
(A) In the absence of epigenetic priming, cells are unable to adopt new cell fates in response to external cues (bue arrow) due
to high epigenetic barriers. However cells with epigenetic priming factors (orange nuclei) have a lowered epigenetic barrier and
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beyond facilitating cell fate transitions, for example following stress or injury or in response to hormonal or
circadian fluctuations.
Possible mechanisms by which epigenetic priming factors may function
Conceptually, epigenetic priming can be thought of in terms of activation barriers which need to be overcome
for a cell to adopt a new fate or function (Figure 2A). The epigenetic plasticity of the cell describes how high
these barriers are. Epigenetic priming factors function by lowering these barriers, facilitating the cell to acquire
new identities. At a molecular level, epigenetic priming factors could function in several ways (Figure 2B). By
binding genomic features, they could prevent repressive DNA methylation from encroaching and silencing the
locus. Priming factors could repel repressive epigenetic modifiers, such as H3K9 histone methyltransferases from
binding, or recruit active epigenetic modifiers such as histone acetyltransferases. Alternatively, they may initiate
antisense transcription that keeps the locus open. This may not directly lead to gene activation, although some
low level of transcription may be observed, but generates a permissive epigenetic landscape to enable activation
of these features upon differentiation. In the absence of the priming factor, the locus may adopt a closed struc-
ture and gain DNA methylation, repressive epigenetic modifiers may now bind, or active epigenetic modifiers
may no longer be effectively recruited. Consequently, the locus is unable to be effectively activated upon differen-
tiation, leading to aberrant gene expression programmes long after the epigenetic priming factor is present.
Dppa2 and Dppa4 as epigenetic priming factors in
development
Emerging research has revealed that the small DNA binding proteins Dppa2/4 act as epigenetic priming factors
and promote cell plasticity in early development. Originally identified in a screen for pluripotency factors [31],
Dppa2/4 are expressed almost exclusively in early embryos (Figure 3). Somewhat perplexingly, zygotic knockout
mice survive early embryogenesis only to succumb from lung and skeletal defects shortly after birth at a time
that Dppa2/4 are no longer expressed [29,30]. This temporal uncoupling of the knockout mouse phenotype
from when the proteins are present is one of the predicted features of epigenetic priming factors and led to
predictions that epigenetic memories from earlier embryonic stages are important for proper development [30].
Dppa2/4 are arranged in tandem in a gene desert on mouse chromosome 16 or human chromosome 3 and, at
least in mouse, are directly regulated by DNA methylation [32] (Figure 3). This keeps the genes silent following
gastrulation through to adulthood, restricting their expression to early embryos and the germline when two
global waves of DNA demethylation occur. These small ∼300 amino acid proteins lack any known enzymatic
activity and instead have a SAP domain that binds DNA, a nuclear localisation signal and conserved C-terminal
domain that associates with histones [29,33]. Dppa2/4 localise to euchromatin [30,33,34] with similar dynamics
as histone H1 [33]. While they have a preference for GC rich promoter DNA, it is currently unknown how
Dppa2/4 are targeted to specific genomic loci. In mouse, Dppa2/4 predominantly form heterodimers which is
likely required for their function as manipulating levels of just one of the two proteins gives largely the same
phenotype as mutating both [30,32]. Dppa2/4 are regulated post-translationally by SUMOylation [35,36] which
inhibits their function. It remains to be uncovered whether additional post-translational modifications are
involved in fine-tuning their activity.
Priming zygotic genome activation
Activation of the embryonic genome following fertilisation represents a major developmental milestone as
control is passed from the oocyte to the embryo proper. Zygotic genome activation takes place in two waves: a
largely promiscuous minor wave followed by a major wave at the two-cell stage in mouse or four-to-eight-cell
Figure 2. Mechanisms and significance of epigenetic priming. Part 2 of 2
can more easily acquire new cell identities or functions in response to external signals (blue arrow). (B) Epigenetic priming
factors (blue) may function at the molecular level at genomic regulatory elements of lineage specific genes (orange bar) by
repelling DNA methylation (filled lollipops), preventing repressive epigenetic modifiers (red) from binding, or promoting active
epigenetic modifiers (green) from binding. Upon differentiation these lineage specific genes can now be readily transcribed. In
the absence of epigenetic priming factors (bottom panel), the epigenetic landscape is remodelled such that it is now no longer
able to be activated efficiently upon differentiation.
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stage in humans (reviewed in [1]). Aspects of zygotic genome activation can be studied in vitro using serum-
grown mouse embryonic stem cells which contain a rare subpopulation of 2C-like cells that share features of
the two-cell embryo [37–40]. Using this model, several studies have revealed an essential role for Dppa2/4 in
Figure 3. Developmental pluripotency associated 2 and 4.
Top panel depicts the Dppa2/4 locus on mouse chromosome 16 or human chromosome 3. Dppa2/4 promoters are
unmethylated in the germ line (top row) and preimplantation embryos (second row) where Dppa2/4 are expressed, and kept
silent by promoter DNA methylation from E7.5 onwards (third row) and throughout the remainder of embryogenesis and in adult
cells (bottom row). Bottom panel depicts the structure of Dppa2 and Dppa4 proteins showing SAP domain that binds DNA
(green) and C-terminal domain (red) that binds histones. Residues sumoylated in ESCs are shown in circles. Numbers
correspond to mouse Dppa2/4. Full length Dppa4 is found in most cell types while an alternatively spliced isoform found
lacking the SAP domain is found in 2-cell embryos.
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regulating 2C-like cells and the ZGA-associated transcripts, including the Zscan4 cluster, MERVL endogenous
retrovirus and LINE1 repeats, expressed in these cells [32,35,41,42].
Dppa2/4 were initially discovered as strong inducers of the 2C-like state through a candidate-based screen
where oocyte/zygotic epigenetic factors were overexpressed in mESCs and the effects on ZGA-like transcription
assessed [32]. This screen approach was recently extended using CRISPR-activation coupled with a single-cell
transcriptomic read out, confirming Dppa2 as a potent activator of ZGA-like transcription in ESCs [41].
Mechanistically, ChIP-seq experiments revealed that Dppa2/4 bind the Dux gene, but not other 2C-like genes or
repeats, regulating its expression [32,35,42]. This is independent of the SAP domain, as a germ-line enriched
isoform of Dppa4 lacking this domain was still able to bind the Dux gene, albeit less strongly [42]. Dux encodes
a transcription factor expressed during the minor wave of ZGA which directly regulates a suite of major wave
transcripts including Zscan4 and MERVL [43–45]. Dppa2/4 are expressed in all ESCs, not just the 2C-like popu-
lation, which raises the question why not all ESCs express these ZGA-like transcripts. However, when viewed
through the lens of an epigenetic priming factor, their presence on the chromatin may be required to keep the
Dux locus open and amenable to future activation upon an additional signal in just a subset of cells.
It has yet to be formally shown whether Dppa2/4 are required to prime ZGA in vivo as maternal stores may
be masking early embryonic phenotypes of the reported zygotic knockout mice. While most Dppa2/4 zygotic
knockout mice die shortly after birth, surviving null animals have reduced fertility, particularly when paired
with another null animal [29,30], although whether this is due to ZGA failure or later developmental defects
remains to be determined. While we wait for thorough characterisation of maternal Dppa2/4 knockouts, several
lines of evidence support a role in fine-tuning priming of ZGA genes in vivo. Injection of a putative dominant
negative form of Dppa2 lacking the SAP domain in zygotes led to 2-cell arrest [46] suggesting that a functional
Dppa2/4 heterodimer may be required. However, too much Dppa2/4 may be just as detrimental as not enough.
Zygotic injection of mutant Dppa2 that is unable to be SUMOylated impaired embryonic development, with
insufficient up-regulation of ZGA transcripts at the two-cell stage [35]. It is unclear whether this mutant also
acts as a dominant negative by sequestering functional Dppa2/4 from its target sites. Further maternal knockout
mouse models will be important to tease apart the precise role of Dppa2/4 in ZGA in vivo, keeping in mind
that phenotypes may be subtle due to the very nature of epigenetic priming factors.
Roles in gastrulation: Dppa2/4 prime bivalent chromatin
Dppa2/4 have recently been shown to have an additional important role in priming the epigenome in pluripotent
cells, facilitating cell differentiation by regulating bivalent chromatin [20,47]. This is achieved by regulating levels
of H3K4me3 and H3K27me3 at these promoters which in turn prevents repressive DNA methylation from accu-
mulating. Deleting either or both Dppa2/4 leads to focal losses of H3K4me3 and H3K27me3 at some but not all
bivalent promoters, and a corresponding accumulation of DNA methylation [20,47]. The epigenetic changes are
reversible as reintroduction of Dppa2/4 into depleted cells restores the epigenetic landscape at these genes [20].
While the precise details of how Dppa2/4 function mechanistically at these genomic loci remains to be deter-
mined, one possibility is that Dppa2/4 are involved in recruiting and/or stabilising the COMPASS and Polycomb
complexes at these loci, either directly or indirectly through modulating local chromatin structure or via antisense
transcription. It will be exciting to explore these, and other models of how Dppa2/4 function in the future.
Interestingly, while Dppa2/4 bind to all bivalent promoters, not all bivalent promoters are affected and those
with higher levels of H3K4me3, higher levels of basal expression and the elongating form of RNA polymerase II
are unaffected by Dppa2/4 loss [20]. The low level of active transcription at these unaffected ‘Dppa2/4-independent’
bivalent promoters may be able to keep these genes primed and bivalent in the absence of the initiating epigenetic
factor(s). The affected ‘Dppa2/4-dependent’ bivalent promoters have less active transcription and so are unable to
maintain their epigenetic status in the absence of Dppa2/4. This reflects one of the features of epigenetic priming
factors in that they are required for the establishment and not necessarily the maintenance of a primed state.
The consequences losing Dppa2/4 and bivalent chromatin are significant. While the pluripotency of the cells
remains unaffected, Dppa2/4 knockout cells are unable to efficiently differentiate in embryoid body assays [20]
or directed endoderm differentiation [47], consistent with observations in previous studies [29,34]. Thus
Dppa2/4 facilitate cellular differentiation and the acquisition of new cell fates. Interestingly, knockout cells
eventually differentiate, albeit at lower frequency, suggesting that priming by Dppa2/4 improves the efficiency
of differentiation rather than acting as a strict gatekeeper. In this way, Dppa2/4 lower the activation threshold
to initiate new transcriptional programmes at a time when the embryo body plan is still being established and
cells need to quickly and dynamically respond to external cues. This may provide a molecular explanation for
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the phenotypes of the zygotic knockout mice [29,30] which survive embryogenesis and are able to generate all
cell types of the three germ layers. It is possible that this not as efficient or delayed in Dppa2/4 knockout
embryos, or that cell identities have subtle defects that are not detrimental until after birth. It will be exciting to
profile Dppa2/4 mutant embryos at early embryonic time points to see if there are shifts in cell composition or
differentiation delays, and link this to any epigenetic alterations in gastrulating embryos. Nonetheless, these
recent studies reveal how epigenetic priming factors, such as Dppa2/4, set the stage for cellular differentiation by
ensuring timely activation of key developmental genes. It is unlikely that Dppa2/4 act alone during this key devel-
opmental window. The lessons learnt from studying Dppa2/4 will aid the discovery other epigenetic priming
factors and add to our understanding of how cell plasticity is regulated epigenetically during development.
Dppa2/4 facilitate reprogramming to pluripotency
Normal development is unidirectional with cells losing potency as they acquire cell fates and the embryo gains
cell complexity, however it is possible to reverse this experimentally and reprogram differentiated somatic cells
to pluripotency. By inducing expression of four transcription factors (Oct4, Klf4, Sox2 and Myc), fully differen-
tiated cells can be reprogrammed to induced pluripotent stem cells (iPSCs), however this is inefficient and
often incomplete. Dppa2/4 are re-expressed in the early stages of reprogramming [48] and mark cells that are
destined to become iPSCs [49]. In addition to being useful markers, Dppa2/4 also have instructive roles in
iPSC reprogramming. While it is possible to generate iPSCs from Dppa4 knockout MEFS [29], the frequency
and efficiency is unclear. Furthermore double Dppa2/4 knockout mouse embryonic fibroblasts (MEFs) fail to
reprogram, and can only be rescued by reintroducing both Dppa2 and Dppa4 together into the cells [50].
Conversely, overexpression of Dppa2/4 greatly enhances both the speed and efficiency of iPSC reprogramming
in both mouse and human cells [50]. This is achieved by remodelling the epigenetic landscape, increasing
global levels of H3K4me3, H3K27ac, H3K27me3 as well as the DNA damage marker γH2A.X, and promoting
an alternative reprogramming trajectory [50]. The binding profile for Dppa2/4 in MEFs is largely the same as
in ESCs [50] suggesting that the forced expression of Dppa2/4 in the differentiated MEFs may facilitate its
acquisition of a pluripotent epigenetic landscape, thereby improving the overall efficiency of reprogramming.
Hijacking developmental epigenetic priming factors in
cancer
While cancer is generally considered a genetic-driven disease, it is becoming more apparent that epigenetic
aberrations have a major contribution to the development and progression of this disease (reviewed in [51]).
The epigenetic landscape usually provides a stable cell identity while priming cells for change. Cancer cells fre-
quently have a distorted cell identity and adapt epigenetic, transcriptomic and phenotypic properties associated
with embryonic cells [52–54]. The epigenome of cancer cells often becomes hyper-plastic, with cancer cells
either activating normally silent transcripts such as early embryonic genes, or failing to activate transcriptional
programmes upon receiving a physiological signal (reviewed in [55]). Epigenetic priming factors, responsible
for establishing this dynamic and permissive landscape, are often deregulated in cancers. For example Dppa2/4
are frequently up-regulated in human cancers including lung [56], ovarian [57], colon [58,59], colorectal [60]
and gastric cancers [61], amongst others [62–66], likely due to the global demethylation that occurs in cancer
cells, and are often associated with poor prognosis [57–61,65]. Currently the majority of studies have been cor-
relative, however there are some research suggesting that Dppa2/4 may be contributing to tumorigenesis.
Overexpression of Dppa2/4 in mouse 3T3 cells is able to transform the cells [63]. Furthermore, Dppa2/4
enhanced soft agar colony formation and increased tumour growth in mouse xenograft experiments [63] sup-
porting a causative role. Future studies will be key to understanding how Dppa2/4, as well as other epigenetic
priming factors, contribute to the initiation, development and metastasis of cancer.
How could an epigenetic priming factor contribute to tumorigenesis? In 1957, Conrad Waddington postu-
lated that development can be depicted as a ball rolling down a mountain in an epigenetic landscape, becoming
progressively restricted with time as it enters valleys and is unable to cross over ridges to access other develop-
mental endpoints (Figure 4) [67]. This restriction can be conceptualised as activation barriers, preventing dif-
ferentiated cells from reverting to earlier more potent states. Epigenetic priming factors may function by
lowering this epigenetic barrier, increasing the epigenetic plasticity and range of identities and phenotypes
available to the cell. Importantly, this does not need to be sustained, once a cell has adopted a new identity or
capability, such as increased stemness or cell motility, it can remain in that state, even if expression of the
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epigenetic priming factor and associated increased epigenetic plasticity is reversed (reviewed in [68]). Normally
during development, the expression and activity of epigenetic priming factors is tightly controlled so that
embryogenesis proceeds in an orderly and regulated manner. However, cancer cells can activate epigenetic
priming factors and increase their epigenetic plasticity. By hijacking these early developmental processes,
cancer cells break free of normal restrictions and control and take on new functions and identities. By increas-
ing our understanding of how epigenetic priming factors function in normal development, we can use the
principles learnt to gain new insights of their contribution to disease.
Perspectives
• Epigenetic priming factors function by increasing the epigenetic plasticity of a cell, poising
promoters or enhancers for future activation. This effectively lowers the ‘epigenetic barrier’ of
the cell, enabling it to adopt new transcriptional programmes more efficiently upon receiving
signals to differentiate during development, or in response to stress, injury or hormonal cues
in adults.
• Dppa2/4 are exemplars of epigenetic priming factors, acting as facilitators of cell fate transi-
tions in early development and reprogramming.
• Developmental epigenetic priming factors may be hijacked in cancers to promote cell plasti-
city and facilitate acquisition of new identities or functions. Mechanistic understanding of the
role of epigenetic priming factors in normal development will provide insights into how they
contribute to disease.
Figure 4. Aberrant expression of epigenetic priming factors may facilitate cancer progression.
At the base of Waddington’s landscape cells are normally restricted in their cell identity, unable to cross the ridges that
separate them from other cell fates (left box). In precancer cells (middle box), aberrant expression of epigenetic priming factors
may lead to heightened epigenetic plasticity (red nucleus), reducing the restrictions on cell identity and enabling cells to
acquire new features. This may be transient as cancers lose expression of the epigenetic priming factor and become locked
into their new cell identity (right box).
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